Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
Risk / Profitability
Risk: High
Profitability: Poor
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy...
Risk factor
Very high price volatility
Weak & very vulnerable to price shocks
Considerable default risk
Profitability factor
Greatly overvalued vs peers
Very low or no dividends
Very poor margins and returns
$ 0.96
About
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy...
